Latest Period
Q4 2025
Security Snapshot
Moderna, Inc. - Common Stock (MRNA) Institutional Ownership
CUSIP: 60770K107
13F Institutional Holders and Ownership History from Q4 2018 to Q1 2026
Institutions Reporting
661
Shares (Excl. Options)
304,072,696
Price
$29.49
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Type / Class
- Equity / Common Stock
- Symbol
- MRNA on Nasdaq
- Shares outstanding
- 397,148,913
- Price per share
- $50.96
- All holders as of 31 Dec 2025
- Q4 2025
- Total 13F shares
- 304,072,696
- Total reported value
- $8,970,169,249
- % of total 13F portfolios
- 0%
- Share change
- +25,422,384
- Value change
- +$762,841,891
- Number of holders
- 661
- Price from insider filings
- $50.96
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- MRNA - Moderna, Inc. - Common Stock is tracked under CUSIP 60770K107.
- 661 institutions reported positions in Q4 2025.
- 3 significant owners is listed from Schedule 13D/13G reporting.
What Changed
- Holder count moved from 661 to 290 between Q4 2025 and Q1 2026.
- Reported value moved from $8,970,169,249 to $1,016,785,945.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Source Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 661 institutions filings for Q4 2025.
Investment Quick Answers
What is CUSIP 60770K107?
CUSIP 60770K107 identifies MRNA - Moderna, Inc. - Common Stock in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.
Next ownership checks
Use the next link that matches the question you still need to answer about this security.
- Latest 13F filings when you want to inspect fresh institutional portfolio moves.
- Latest Schedule 13D/13G reports when you need large-owner changes outside the 13F cycle.
- All institutional ownership pages to compare this security with other holder-history pages.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 60770K107:
Significant Owners of Moderna, Inc. - Common Stock (MRNA) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| FMR LLC | 11% | +49% | $1,217,980,317 | +$393,401,259 | 41,301,469 | +48% | FMR LLC | 30 Jan 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC | 6.5% | $1,317,438,259 | 25,933,824 | Vanguard Capital Management | 31 Mar 2026 | |||
| BAILLIE GIFFORD & CO | 5.3% | -17% | $814,988,354 | -$172,974,542 | 20,580,514 | -18% | BAILLIE GIFFORD & CO | 31 Dec 2025 |
As of 31 Dec 2025, 661 institutional investors reported holding 304,072,696 shares of Moderna, Inc. - Common Stock (MRNA). This represents 77% of the company’s total 397,148,913 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of Moderna, Inc. - Common Stock (MRNA) together control 62% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| VANGUARD GROUP INC | 10% | 41,584,782 | +0.97% | 0.02% | $1,226,335,222 |
| BlackRock, Inc. | 8.2% | 32,505,733 | +10% | 0.02% | $958,594,060 |
| FMR LLC | 7.1% | 28,045,311 | +128% | 0.04% | $827,056,216 |
| BAILLIE GIFFORD & CO | 5.2% | 20,580,514 | -5.8% | 0.5% | $606,919,358 |
| STATE STREET CORP | 4.1% | 16,365,478 | -4.3% | 0.02% | $482,617,946 |
| Capital World Investors | 3.2% | 12,828,040 | 0.05% | $378,298,900 | |
| GEODE CAPITAL MANAGEMENT, LLC | 2.3% | 9,219,644 | -0.32% | 0.02% | $271,415,217 |
| MORGAN STANLEY | 2.2% | 8,870,716 | -11% | 0.02% | $261,597,450 |
| Theleme Partners LLP | 2% | 8,081,810 | +0.16% | 16% | $238,332,577 |
| TWO SIGMA ADVISERS, LP | 1.9% | 7,729,700 | +14% | 0.44% | $227,948,853 |
| TWO SIGMA INVESTMENTS, LP | 1.8% | 7,342,096 | -2.5% | 0.32% | $216,518,411 |
| Invesco Ltd. | 1.8% | 7,029,694 | -14% | 0.03% | $207,305,681 |
| D. E. Shaw & Co., Inc. | 1.3% | 5,182,759 | -16% | 0.12% | $152,839,563 |
| Flagship Pioneering, LLC | 1.2% | 4,632,149 | 0% | 42% | $136,602,075 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 1.2% | 4,621,558 | +7.2% | 0.02% | $136,289,758 |
| BNP PARIBAS FINANCIAL MARKETS | 1% | 4,152,432 | 0% | 0.08% | $122,455,220 |
| UBS Group AG | 1% | 4,086,766 | -15% | 0.02% | $120,518,730 |
| GOLDMAN SACHS GROUP INC | 0.99% | 3,950,619 | +24% | 0.02% | $116,503,752 |
| Alyeska Investment Group, L.P. | 0.81% | 3,228,531 | 0.27% | $95,209,379 | |
| BANQUE PICTET & CIE SA | 0.79% | 3,130,724 | 0% | 0.92% | $92,325,051 |
| NORTHERN TRUST CORP | 0.76% | 3,002,578 | +3.3% | 0.01% | $88,546,025 |
| NORGES BANK | 0.68% | 2,702,832 | 0.01% | $79,706,516 | |
| Merck & Co., Inc. | 0.58% | 2,308,190 | 0% | 25% | $68,068,523 |
| FEDERATED HERMES, INC. | 0.55% | 2,178,537 | -22% | 0.11% | $64,245,055 |
| NATIONAL BANK OF CANADA /FI/ | 0.54% | 2,156,275 | -20% | 0.07% | $63,588,550 |
Institutional Holders of Moderna, Inc. - Common Stock (MRNA) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 20,125,215 | $1,016,785,945 | -$29,576,194 | $50.80 | 290 |
| 2025 Q4 | 304,072,696 | $8,970,169,249 | +$762,841,891 | $29.49 | 661 |
| 2025 Q3 | 275,125,683 | $7,105,644,631 | -$450,789,607 | $25.83 | 634 |
| 2025 Q2 | 291,423,621 | $8,041,462,409 | +$359,301,164 | $27.59 | 663 |
| 2025 Q1 | 278,813,548 | $7,903,142,271 | -$59,165,632 | $28.35 | 678 |
| 2024 Q4 | 276,578,373 | $11,499,056,660 | +$341,051,932 | $41.58 | 729 |
| 2024 Q3 | 260,519,054 | $17,396,828,362 | -$359,670,897 | $66.83 | 765 |
| 2024 Q2 | 261,395,055 | $31,036,767,708 | -$43,788,037 | $118.75 | 939 |
| 2024 Q1 | 262,225,074 | $27,942,962,472 | +$671,576,108 | $106.56 | 887 |
| 2023 Q4 | 256,350,763 | $25,504,353,761 | +$907,888,206 | $99.45 | 869 |
| 2023 Q3 | 246,373,071 | $25,443,040,671 | -$303,969,124 | $103.29 | 872 |
| 2023 Q2 | 246,506,415 | $29,955,571,272 | -$272,422,709 | $121.50 | 942 |
| 2023 Q1 | 249,344,037 | $38,273,515,844 | +$239,644,701 | $153.58 | 996 |
| 2022 Q4 | 248,479,248 | $44,642,318,628 | +$419,105,140 | $179.62 | 1,049 |
| 2022 Q3 | 246,689,392 | $29,178,218,716 | +$223,399,465 | $118.25 | 882 |
| 2022 Q2 | 244,256,119 | $34,891,994,437 | -$466,757,538 | $142.85 | 957 |
| 2022 Q1 | 248,043,088 | $42,733,575,812 | +$209,409,354 | $172.26 | 983 |
| 2021 Q4 | 246,080,857 | $62,455,582,704 | -$6,658,229 | $253.98 | 1,078 |
| 2021 Q3 | 225,302,088 | $86,681,348,769 | +$6,751,024,992 | $384.86 | 1,120 |
| 2021 Q2 | 207,880,167 | $48,837,794,090 | +$5,169,371,723 | $234.98 | 873 |
| 2021 Q1 | 188,072,205 | $24,617,994,062 | +$2,907,518,589 | $130.95 | 752 |
| 2020 Q4 | 168,732,531 | $17,626,423,609 | -$527,763,419 | $104.47 | 688 |
| 2020 Q3 | 204,933,447 | $14,493,668,331 | -$999,957,835 | $70.75 | 535 |
| 2020 Q2 | 219,125,612 | $14,064,229,526 | +$1,607,162,122 | $64.21 | 477 |
| 2020 Q1 | 195,768,954 | $5,863,724,828 | +$637,559,905 | $29.95 | 285 |
| 2019 Q4 | 174,185,916 | $3,406,689,342 | +$267,799,940 | $19.56 | 157 |
| 2019 Q3 | 109,780,342 | $1,747,630,941 | +$415,283,859 | $15.92 | 131 |
| 2019 Q2 | 84,483,070 | $1,235,871,867 | +$117,389,510 | $14.64 | 128 |
| 2019 Q1 | 79,523,801 | $1,604,234,442 | +$101,479,383 | $20.35 | 101 |
| 2018 Q4 | 133,583,585 | $2,019,181,000 | +$2,019,011,980 | $15.27 | 75 |